Cuprina Holdings (Cayman) Limited Class A (CUPR)
NASDAQ:CUPR
Top Page
Cuprina Holdings (Cayman) Limited Class A
(NASDAQ:CUPR)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.40
▲(6.05% Upside)
Action:UpgradedDate:01/31/26
The score is driven primarily by weak financial performance (sharp revenue decline, negative margins, negative equity, and negative operating/free cash flow). Technicals also remain bearish with the stock below major moving averages and a negative MACD. Valuation provides limited support given the negative P/E and no dividend yield data.
Positive Factors
Strategic JV expands product pipeline
The JV opens a clear, durable entry into the wound care market with planned clinical studies in 2026 and exposure to a large, growing addressable market. Successful development and approval would create a recurring product revenue stream beyond current offerings.
Negative Factors
Sharp revenue decline
A >50% revenue drop signals loss of customer traction or failed commercialization, undermining the company’s ability to scale. Continued top-line contraction pressures margins, hampers reinvestment capacity, and increases dependence on external capital to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic JV expands product pipeline
The JV opens a clear, durable entry into the wound care market with planned clinical studies in 2026 and exposure to a large, growing addressable market. Successful development and approval would create a recurring product revenue stream beyond current offerings.
Read all positive factors
Cuprina Holdings (Cayman) Limited Class A (CUPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.19M
Dividend YieldN/A
Average Volume (3M)2.90M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,365,000
10 Day Avg. Volume197,362
30 Day Avg. Volume2,899,437
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)-27.64
Price to Sales (P/S)2550.55
P/FCF Ratio-97.98
Enterprise Value/Market Cap38.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model
Company Description
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile...
Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
20
Very Negative
Cash Flow
25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 48.32K | 100.77K | 56.60K | 58.50K |
| Gross Profit | -3.02K | 36.60K | 19.98K | 23.06K |
| EBITDA | -1.43M | -994.12K | -1.06M | -489.44K |
| Net Income | -1.56M | -1.12M | -1.09M | -519.69K |
Balance Sheet | ||||
| Total Assets | 1.75M | 1.59M | 1.44M | 953.05K |
| Cash, Cash Equivalents and Short-Term Investments | 116.47K | 35.26K | 564.58K | 767.29K |
| Total Debt | 254.79K | 121.82K | 183.63K | 170.03K |
| Total Liabilities | 6.20M | 4.48M | 3.21M | 1.64M |
| Stockholders Equity | -4.46M | -2.90M | -1.78M | -683.52K |
Cash Flow | ||||
| Free Cash Flow | -1.26M | -1.61M | -1.87M | -224.72K |
| Operating Cash Flow | -1.24M | -1.54M | -1.85M | -221.86K |
| Investing Cash Flow | -21.88K | -67.98K | -31.28K | -2.86K |
| Financing Cash Flow | 1.34M | 1.08M | 1.68M | 991.39K |
Cuprina Holdings (Cayman) Limited Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $103.46M | -1.56 | 1028.60% | ― | 87.45% | 72.30% | |
43 Neutral | $1.59M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
41 Neutral | $3.19M | -4.33 | ― | ― | ― | ― | |
39 Underperform | $394.39K | ― | -1302.82% | ― | ― | 99.09% | |
| ― | $4.19M | -0.25 | -9999.00% | ― | ― | 79.31% |
* Healthcare Sector Average
CUPR
Cuprina Holdings (Cayman) Limited Class A
0.43
-3.72
-89.59%
BDRX
Biodexa Pharmaceuticals
3.51
-74.99
-95.53%
HSDT
Solana Company
1.88
-240.90
-99.23%
WINT
Windtree Therapeutics
0.01
-1.30
-99.16%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.75
-9.63
-92.77%
Cuprina Holdings (Cayman) Limited Class A Corporate Events
Cuprina Holdings Releases Mid-2025 Financial Results
Dec 9, 2025
Cuprina Holdings (Cayman) Limited released its unaudited financial results for the six months ending June 30, 2025, on December 9, 2025. The report includes financial statements and management’s analysis, highlighting the company’s fin...
Cuprina Holdings Receives Nasdaq Notice for Bid Price Deficiency
Nov 28, 2025
On November 26, 2025, Cuprina Holdings received a notice from Nasdaq indicating that its Class A ordinary shares had fallen below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has been given a 180-day compli...
Cuprina Holdings Forms Joint Venture with Aiodine for Iodine-Based Wound Care
Nov 18, 2025
On November 18, 2025, Cuprina Holdings announced a joint venture with Aiodine Laboratory to develop and market a novel iodine-based solution for wound care therapy. This partnership aims to utilize Aiodine’s proprietary iodine technology to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.